Stock Events

Stock Events

Abeona Therapeutics 

$0.000000
105
-$0.01-100% Friday 22:07

Statistics

Day High
-
Day Low
-
52W High
0.004
52W Low
0.004
Volume
-
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

20MayExpected
Q3 2024
Q4 2024
Q2 2025
Q3 2025
Q4 2025
Q1 2026
-0.63
0.15
0.93
1.71
Expected EPS
-0.335
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-63.73MNet Income

Analyst Ratings

20.50Average Price Target
The highest estimate is 21.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on developing therapies for neurological and neurodegenerative diseases, directly competing with Abeona's gene therapy approach for similar disorders.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad portfolio including gene therapies targeting rare diseases, overlapping with Abeona's focus areas.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for rare diseases, directly competing with Abeona's rare disease focus.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.52B
Ultragenyx Pharmaceutical targets rare and ultra-rare diseases with its drug development, similar to Abeona's focus.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics and gene therapy for rare diseases, competing with Abeona's gene therapy approach.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals engages in developing therapies for treating cystic fibrosis and other serious diseases, competing in the rare disease market with Abeona.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk focuses on a broad range of treatments including for rare diseases, potentially competing with Abeona in the gene therapy and rare disease market.

About

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.
Show more...
CEO
Mr. Michael Amoroso
Employees
76
Country
United States

Listings

F
DE
PCJ.F
STU
DE
PCJ.STU
STU
DE
PCJP.STU
BOATS
BOATS
ABEO.BOATS

0 Comments

Share your thoughts

FAQ

What is Abeona Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Abeona Therapeutics stocks are traded under the ticker AKC.
Is Abeona Therapeutics stock price growing?▼
AKC stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Abeona Therapeutics has showed a +0% increase.
What is Abeona Therapeutics revenue for the last year?▼
Abeona Therapeutics revenue for the last year amounts to 0 USD.
What is Abeona Therapeutics net income for the last year?▼
AKC net income for the last year is -63.73M USD.
How many employees does Abeona Therapeutics have?▼
As of September 04, 2026, the company has 76 employees.
In which sector is Abeona Therapeutics located?▼
Abeona Therapeutics operates in the Health & Wellness sector.
When did Abeona Therapeutics complete a stock split?▼
Abeona Therapeutics has not had any recent stock splits.
Where is Abeona Therapeutics headquartered?▼
Abeona Therapeutics is headquartered in New York, United States.